Prognostic value of serum M-protein doubling time at escape from plateau of multiple myeloma

European Journal of Haematology

Volumn 57, Issue 3, 1996, Pages 247-253

  Oivanen, Tiina M ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Chemotherapy; Multiple myeloma; Plateau; Relapse

Indexed keywords

CYCLOPHOSPHAMIDE; M PROTEIN; MELPHALAN; METHYLPREDNISOLONE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0029972174     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb01371.x     Document Type: Article

References (17)

1. DURIE BGM, RUSSELL DH, SALMON SE. Reappraisal of plateau phase in myeloma. Lancet 1980: 12: 65-67.
2. JOSHUA DE, SNOWDON I, GIBSON J, et al. Multiple myeloma: plateau phase revisited. Hemat Rev 1991: 5: 59-66.
3. OIVANEN TM for the FINNISH LEUKAEMIA GROUP. Plateau phase in multiple myeloma. An analysis of longterm follow-up of 432 patients. Br J Haemat 1996: 92: 834-839.
4. ALEXANIAN R, GEHAN E, HAUT A, SAIKI J, WEICK J. Unmaintained remissions in multiple myeloma. Blood 1978: 51: 1005-1011.
5. SALMON SE. Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin Hematol 1973: 10:135-147.
6. BELCH A, SHELLEY W, BERGSAGEL D, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988: 57: 94-99.
7. FINNISH LEUKAEMIA GROUP. Aggressive combination chemotherapy in multiple myeloma. A multicentre trial. Scand J Haematol 1985: 35: 205-209.
8. FINNISH LEUKAEMIA GROUP. Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone: a randomised multicentre trial. Eur J Haematol 1987: 38: 50-54.
9. FINNISH LEUKAEMIA GROUP. Treatment of multiple myeloma in old patients. Eur J Haematol 1989: 43: 328-331.
10. FINNISH LEUKAEMIA GROUP. Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Eur J Haematol 1993: 51: 98-101.
11. FINNISH LEUKAEMIA GROUP. Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Eur J Haematol 1990: 44: 121-124.
12. DURIE BGM, SALMON SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975: 36: 842-854.
13. CHRONIC LEUKEMIA-MYELOMA TASK FORCE. Proposed guidelines for clinical studies. Cancer Chemother Rep 1973: 4: 145-158.
14. HOBBS JR. Growth rates and responses to treatment in human myelomatosis. Br J Haematol 1969: 16: 607-617.
15. JOSHUA DE, BROWN RD, GIBSON J. Multiple myeloma: why does the disease escape from plateau phase? Br J Haemat 1994: 88: 667-671.
16. ALEXANIAN R, DIMOPOULOS MA, HESTER J, DELASALLE K, CHAMPLIN R. Early myeloablative therapy for multiple myeloma. Blood 1994: 84: 4278-4282.
17. ALEXANIAN R, DIMOPOULOS M, SMITH T, DELASALLE K, BARLOGIE B, CHAMPLIN R. Limited value of myeloablative therapy for late multiple myeloma. Blood 1994: 83: 512-516.